DelveInsight’s, “Hypertrophic cardiomyopathy - Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Hypertrophic cardiomyopathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

    Geography Covered
    • Global coverage
    Hypertrophic cardiomyopathy Understanding
    Hypertrophic cardiomyopathy: Overview
    Hypertrophic cardiomyopathy (HCM) is a disease in which the heart muscle becomes abnormally thick (hypertrophied). The thickened heart muscle can make it harder for the heart to pump blood. Signs and symptoms of HCM include: Chest pain, especially with physical exertion, Shortness of breath, especially with physical exertion, Fatigue, Arrhythmias (abnormal heart rhythms), Dizziness, Lightheadedness, Fainting (syncope), swelling in the ankles, feet, legs, abdomen and veins in the neck.
    Hypertrophic cardiomyopathy is most often inherited. HCM is the most common form of genetic heart disease. It can happen at any age, but most receive a diagnosis in middle age. HCM is diagnosed based on medical history, family history, a physical exam and diagnostic test results.
    Medications called beta-blockers, calcium channel blockers and diuretics offer limited and varying relief of symptoms. They may help with function but may also have adverse side effects. A range of surgical and nonsurgical procedures can be used to treat HCM: Septal myectomy- Septal myectomy is open-heart surgery. Alcohol septal ablation (nonsurgical procedure) - In this procedure, ethanol (a type of alcohol) is injected through a tube into the small artery that supplies blood to the area of heart muscle thickened by HCM. Surgically implanted devices – Surgeons can implant several types of devices to help the heart work better, including: Implantable cardioverter defibrillator (ICD), Pacemaker, Cardiac resynchronization therapy (CRT) device. Heart transplant – In HCM patients with advanced, end-stage disease, a heart transplant may be considered. In this procedure, a person’s diseased heart is replaced with a healthy donor heart.


    Report Highlights
    • The companies and academics are working to assess challenges and seek opportunities that could influence Hypertrophic cardiomyopathy R&D. The therapies under development are focused on novel approaches for Hypertrophic cardiomyopathy.
    Hypertrophic cardiomyopathy Emerging Drugs Chapters
    This segment of the Hypertrophic cardiomyopathy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
    Hypertrophic cardiomyopathy Emerging Drugs
    • Mavacamten: MyoKardia
    Mavacamten is a first-in-class, oral, allosteric modulator of cardiac myosin in development for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). In March, 2021, The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for mavacamten, a novel therapy for symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
    In May, 2021, Bristol Myers Squibb announced that data from multiple studies across the company’s clinical program investigating mavacamten in patients with obstructive hypertrophic cardiomyopathy (oHCM) will be presented at the upcoming American College of Cardiology’s 70th Annual Scientific Session (ACC.21).
    • IMB-1018972: Imbria pharmaceticals
    IMB-1018972 is a novel, investigational cardiac mitotrope in development for the treatment of cardiovascular disease. As a partial fatty acid oxidation (pFOX) inhibitor, IMB-101 is designed to shift myocardial substrate utilization in favor of glucose oxidation to generate more ATP per unit of oxygen consumed thereby increasing myocardial metabolic efficiency.
    It is currently in Phase II stage of development for Hypertrophic cardiomyopathy and is being developed by Imbria pharmaceticals.
    Further product details are provided in the report??..

    Hypertrophic cardiomyopathy: Therapeutic Assessment
    This segment of the report provides insights about the different Hypertrophic cardiomyopathy drugs segregated based on following parameters that define the scope of the report, such as:
    • Major Players working on Hypertrophic cardiomyopathy
    There are approx. 5+ key companies which are developing the Hypertrophic cardiomyopathy. The companies which have their Hypertrophic cardiomyopathy drug candidates in the most advanced stage, i.e. Preregistration include, MyoKardia.
    • Phases
    DelveInsight’s report covers around 5+ products under different phases of clinical development like
    • Late-stage products (Phase III)
    • Mid-stage products (Phase II)
    • Early-stage products (Phase I/II and Phase I) along with the details of
    • Pre-clinical and Discovery stage candidates
    • Discontinued & Inactive candidates
    • Route of Administration
    Hypertrophic cardiomyopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
    • Infusion
    • Intradermal
    • Intramuscular
    • Intranasal
    • Intravaginal
    • Oral
    • Parenteral
    • Subcutaneous
    • Topical
    • Molecule Type
    Products have been categorized under various Molecule types such as
    • Vaccines
    • Monoclonal Antibody
    • Peptides
    • Polymer
    • Small molecule
    • Product Type
    Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

    Hypertrophic cardiomyopathy: Pipeline Development Activities
    The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Hypertrophic cardiomyopathy therapeutic drugs key players involved in developing key drugs.
    Pipeline Development Activities
    The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hypertrophic cardiomyopathy drugs.

    Hypertrophic cardiomyopathy Report Insights
    • Hypertrophic cardiomyopathy Pipeline Analysis
    • Therapeutic Assessment
    • Unmet Needs
    • Impact of Drugs
    Hypertrophic cardiomyopathy Report Assessment
    • Pipeline Product Profiles
    • Therapeutic Assessment
    • Pipeline Assessment
    • Inactive drugs assessment
    • Unmet Needs

    Key Questions
    Current Scenario and Emerging Therapies:
    • How many companies are developing Hypertrophic cardiomyopathy drugs?
    • How many Hypertrophic cardiomyopathy drugs are developed by each company?
    • How many emerging drugs are in mid-stage, and late-stage of development for Hypertrophic cardiomyopathy?
    • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Hypertrophic cardiomyopathy therapeutics?
    • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
    • What are the clinical studies going on for Hypertrophic cardiomyopathy and their status?
    • What are the key designations that have been granted to the emerging drugs?

    Key Players
    • Imbria pharmaceticals
    • Cytokinetics
    • MyoKardia
    • Celltrion
    • Tenaya Therapeutics

    Key Products
    • IMB-1018972
    • CK-3773274
    • Mavacamten
    • CT-G20